Melphalan, has been a major component of myeloma therapy since the 1950s. In the context
of hematopoietic cell transplantation (HCT), high dose melphalan (HDM) is the most …

Busulfan is an alkylating drug routinely used in conditioning regimens for allogeneic
hematopoietic cell transplantation (allo-HCT). A myeloablative conditioning regimen …

In this issue of Blood Advances, Dvorak et al 1 enhanced our understanding of the impact of
rabbit antithymocyte globulin (rATG) exposure on outcomes after allogeneic hematopoietic …

Melphalan flufenamide (melflufen) is a novel lipophilic peptide–drug conjugate recently
approved in the European Union and the United Kingdom for the treatment of relapsed …

Cyclophosphamide (CY) is an alkylating agent widely used in the field of oncology and
hematopoietic cell transplantation (HCT). It is recommended to use an adjusted body weight …

As a hydrolysis mediated drug in vivo, the pharmacokinetics of melphalan are highly
variable in patients. Few methodologies could simultaneously measure the concentrations …

Hematopoietic cell transplantation requires higher doses of chemotherapy, and practices of
adjusting the weight because of concerns of organ toxicity are common. This retrospective …

High-dose melphalan is one of the main cytotoxic DNA alkylating agents and is used in
many transplantation conditioning regimens. Studies have shown a wide range of drug …